74d58c33-0c42-47bc-a55b-f56835480fbe
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 48.807665982204
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.500
- MITOTIC_SPINDLE+0.330
- SPERMATOGENESIS+0.240
- HEDGEHOG_SIGNALING+0.190
- PANCREAS_BETA_CELLS+0.180
- UV_RESPONSE_DN+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
- ANDROGEN_RESPONSE+0.140
- KRAS_SIGNALING_DN+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.660
- INTERFERON_GAMMA_RESPONSE-0.550
- OXIDATIVE_PHOSPHORYLATION-0.460
- IL6_JAK_STAT3_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.420
- ALLOGRAFT_REJECTION-0.410
- P53_PATHWAY-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- INFLAMMATORY_RESPONSE-0.340
- ANGIOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 766e896b-b5a2-49ee-be4c-e95670a16fdc | — | — | 0.873 |
| 2 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.863 |
| 3 | de92b16c-4549-4025-9885-76c260c30cf7 | — | — | 0.854 |
| 4 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.847 |
| 5 | ERR2598213 | fetal | fetal | 0.844 |
| 6 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.843 |
| 7 | BS_AWH9757B | high-grade glioma | — | 0.842 |
| 8 | ad30e5e1-182b-4758-8e70-53e0bcf78072 | — | — | 0.837 |
| 9 | SRR8613800 | — | D | 0.833 |
| 10 | BS_KABQQA0T | Diffuse intrinsic pontine glioma | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |